Placental growth factor in cancer

Expert Opin Ther Targets. 2014 Nov;18(11):1339-54. doi: 10.1517/14728222.2014.948420. Epub 2014 Oct 9.


Introduction: Placental growth factor (PLGF) belongs to the VEGF family, which among the three VEGF receptors binds exclusively to VEGFR1, present on various cell types. Isoform PLGF-2 also binds the neuropilin co-receptors. PLGF is dispensable for development and health but has a prominent role in pathology including cancer. This has triggered the question whether PLGF targeting might offer an alternative to current antiangiogenesis therapy, which encounters problems of refractoriness and acquired resistance.

Areas covered: This article reviews the available literature on the characteristics of PLGF, its role(s) in cancer and the findings on PLGF inhibition in preclinical models with attention to as yet unresolved questions and summarizes data from initial clinical trials.

Expert opinion: Preclinical studies show that inhibition of PLGF, either by genetic inhibition or by pharmacological blockade using distinct independently generated anti-PLGF antibodies, slows down tumor growth and metastasis and even induces regression of pre-existing medulloblastoma, the most frequent brain cancer in children. These promising preclinical findings, together with the acceptable safety profile of anti-PLGF administration in Phase I clinical trials, have attracted attention to PLGF as a potential target for therapy.

Keywords: angiogenesis; cancer; inflammation; macrophage polarization; metastasis; placental growth factor; targeted therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Child
  • Clinical Trials as Topic
  • Drug Design
  • Drug Evaluation, Preclinical
  • Drug Resistance, Neoplasm
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Placenta Growth Factor
  • Pregnancy Proteins / antagonists & inhibitors*
  • Pregnancy Proteins / genetics
  • Pregnancy Proteins / metabolism


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • PGF protein, human
  • Pregnancy Proteins
  • Placenta Growth Factor